# Clinical Study to Evaluate the Efficacy, Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Influenza Vaccine Compared to Non-influenza Vaccine Comparator in Adults ≥ 65 Years of Age

> **NCT02587221** · PHASE3 · COMPLETED · sponsor: **Seqirus** · enrollment: 6790 (actual)

## Conditions studied

- Influenza

## Interventions

- **BIOLOGICAL:** MF59-adjuvanted Quadrivalent Subunit Inactivated Egg-derived Influenza Vaccine (aQIV)
- **BIOLOGICAL:** Non-Influenza Comparator (Boostrix)

## Key facts

- **NCT ID:** NCT02587221
- **Lead sponsor:** Seqirus
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2016-09-30
- **Primary completion:** 2018-07-23
- **Final completion:** 2018-07-23
- **Target enrollment:** 6790 (ACTUAL)
- **Last updated:** 2020-06-17


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02587221

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02587221, "Clinical Study to Evaluate the Efficacy, Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Influenza Vaccine Compared to Non-influenza Vaccine Comparator in Adults ≥ 65 Years of Age". Retrieved via AI Analytics 2026-06-24 from https://api.ai-analytics.org/clinical/NCT02587221. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*